Galera Therapeutics (NASDAQ:GRTX) Trading Down 3.8%

Galera Therapeutics, Inc. (NASDAQ:GRTX)’s share price dropped 3.8% during mid-day trading on Monday . The stock traded as low as $0.15 and last traded at $0.15. Approximately 563,079 shares changed hands during mid-day trading, a decline of 74% from the average daily volume of 2,196,599 shares. The stock had previously closed at $0.16.

Galera Therapeutics Price Performance

The firm’s 50 day moving average price is $0.20 and its 200-day moving average price is $0.17. The firm has a market cap of $8.32 million, a price-to-earnings ratio of -0.11 and a beta of 2.17.

Institutional Investors Weigh In On Galera Therapeutics

Institutional investors have recently bought and sold shares of the business. LPL Financial LLC boosted its stake in Galera Therapeutics by 15.5% during the second quarter. LPL Financial LLC now owns 37,235 shares of the company’s stock worth $116,000 after buying an additional 5,000 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of Galera Therapeutics by 90.8% in the 1st quarter. Jane Street Group LLC now owns 19,853 shares of the company’s stock valued at $51,000 after purchasing an additional 9,450 shares in the last quarter. State Street Corp boosted its stake in shares of Galera Therapeutics by 187.7% in the 1st quarter. State Street Corp now owns 82,764 shares of the company’s stock valued at $212,000 after purchasing an additional 54,000 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Galera Therapeutics by 12.2% in the 1st quarter. Geode Capital Management LLC now owns 196,240 shares of the company’s stock valued at $502,000 after purchasing an additional 21,316 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Galera Therapeutics in the 1st quarter valued at $348,000. Institutional investors and hedge funds own 50.77% of the company’s stock.

Galera Therapeutics Company Profile

Galera Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy.